Crohn's Disease clinical trials at UC Irvine
4 in progress, 1 open to eligible people
A Study of CDPATH™ to Help Manage and Treat Crohn's Disease
open to eligible people ages 18 years and up
CDPATH™ is a tool to help predict the potential for developing Crohn's disease related complications in certain adult participants within 3 years. The main aim of the study is to explore the use of CDPATH™ to describe a participant's risk profile and to have discussions with their doctor about the potential path of their Crohn's disease. The number of visits will be decided by the study clinic according to their standard practice.
Orange, California and other locations
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
Sorry, not currently recruiting here
The purpose of this study is to evaluate the efficacy of JNJ-78934804 at Week 48 compared to guselkumab and golimumab.
Orange, California and other locations
A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
Sorry, in progress, not accepting new patients
The reason for this study is to see if the study drug mirikizumab is safe and effective in participants with moderately to severely active Crohn's disease.
Orange, California and other locations
Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Participants With Crohn's Disease (CD)
Sorry, in progress, not accepting new patients
The purpose of this study is to evaluate the combined remission of complex perianal fistulas, defined as the clinical assessment at Week 24 of closure of all treated external openings that were draining at baseline despite gentle finger compression, and absence of collections greater than (>) 2 centimeter (cm) (in at least 2 dimensions) confirmed by blinded central magnetic resonance imaging (MRI) assessment at Week 24.
Orange, California and other locations
Our lead scientists for Crohn's Disease research studies include Nimisha Parekh.
Last updated: